Why the study?
Data on glucagon-like peptide-1 receptor agonists in transthyretin amyloid cardiomyopathy with type 2 diabetes mellitus remain scarce.
Does GLP-1 RA use improve clinical outcomes in adult patients with ATTR-CM and concomitant type 2 diabetes mellitus?
Cohort (n=2,538)
Yes
Does GLP-1 RA use improve clinical outcomes in adult patients with ATTR-CM and concomitant type 2 diabetes mellitus?
GLP-1 receptor agonists are associated with improved 1-year cardiovascular outcomes and lower mortality in patients with ATTR-CM and concurrent type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in ATTR-CM with diabetes; leaves open potential benefit of GLP-1 RAs pending RCTs.
Transthyretin amyloid cardiomyopathy (ATTR-CM) leads to heart failure (HF), with limited therapies available. Data on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in ATTR-CM and type-2 diabetes mellitus (T2DM) remain scarce. Using the TriNetX Global Collaborative Research Network (2005-2025), we identified adults with ATTR-CM and concomitant T2DM and stratified them by GLP-1 RA use, and performed 1:1 propensity-score matching. A total of 1269 matched pairs were analyzed. At 1 year, GLP-1 RA use was associated with lower all-cause mortality, HF events, myocardial infarction, stroke, major adverse cardiac and cerebrovascular events, arrhythmias, and rehospitalization. GLP-1 RA use may improve outcomes in ATTR-CM patients with T2DM.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2026) conducted a cohort in Transthyretin amyloid cardiomyopathy (ATTR-CM) with type-2 diabetes mellitus (T2DM) (n=2,538). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) vs. No GLP-1 RA use was evaluated on All-cause mortality, HF events, myocardial infarction, stroke, major adverse cardiac and cerebrovascular events, arrhythmias, and rehospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: